Androgenetic Alopecia, Hair Follicle Miniaturization, and Oral Minoxidil Treatment Strategies

Conclusions

• The presentation concludes that androgenetic alopecia is not explained by androgen signaling alone, but by a more complex cycle of hair-shedding, follicular-unit changes, and stem-cell niche disruption.
• It argues that increased hair shedding and shortened anagen often precede visible miniaturization and baldness, rather than the other way around.
• The talk suggests that telogen effluvium may be a prerequisite or early inciting event for common pattern baldness in both men and women.
• It concludes that follicular miniaturization develops over multiple hair cycles through progressive loss and failed replacement of dermal papilla cells.
• The research supports a model in which disruption of the arrector pili muscle and follicular-unit architecture marks progression toward irreversible alopecia.
• It concludes that minoxidil and finasteride can both reverse miniaturization, but minoxidil has broader effects because it also initiates anagen, delays catagen, and increases growth rate.
• The presentation finds evidence that oral and sublingual minoxidil can produce dose-dependent increases in hair fiber diameter and hair density.
• It concludes that low-dose oral minoxidil is generally safe when started cautiously and monitored appropriately, with side effects usually dose-related and manageable.
• The talk recommends that oral minoxidil be introduced gradually, with patient counseling about early shedding, cardiovascular risks, and the need for long-term treatment.
• It concludes that finasteride is more useful for vertex-predominant hair loss, while minoxidil is effective across frontal, temporal, vertex, and even occipital scalp regions.
• The presentation suggests that dutasteride should be reserved for selected patients because its adverse sexual effects may be more persistent despite its potency.
• Overall, the research presented favors a stepwise, combination-based treatment approach that begins with minoxidil and escalates therapy based on response and tolerability.